Ticker Hub
PFE — AI Analysis & Sentiment
9 recent AI-generated analyses for PFE. Sentiment and confidence insights updated continuously.
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer's latest clinical data for BRAFTOVI in mCRC demonstrates significant survival benefits, strengthening its market position and revenue potent...
May 31, 2026Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer's LORBRENA demonstrated exceptional long-term efficacy, reinforcing its market position and contributing significantly to future earnings po...
May 29, 2026Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer's strategic collaboration with Innovent Biologics significantly enhances its oncology pipeline, securing future growth in a critical therape...
May 28, 2026Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Pfizer's strong Phase 2 vaccine data and pivotal Phase 3 initiation de-risk a critical pipeline asset, pointing to future market expansion and reve...
May 20, 2026European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
Pfizer's HYMPAVZI received EU approval for expanded use in hemophilia, opening a new market segment for a difficult-to-treat patient population. Th...
May 13, 2026Pfizer Reaches Three Settlement Agreements for VYNDAMAX
Pfizer's patent settlement for VYNDAMAX extends revenue stability until 2031, avoiding an earlier anticipated decline. This secures a significant r...
Apr 28, 2026TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Positive Phase 3 results for TALZENNA/XTANDI in metastatic prostate cancer create a strong catalyst for Pfizer, expanding revenue potential for a k...
Mar 19, 2026Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Positive Phase 2 trial results for Atirmociclib significantly boost Pfizer's oncology pipeline, offering a potential first-in-class treatment for m...
Mar 17, 2026PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Pfizer's PADCEV + Keytruda achieved superior efficacy in a Phase 3 bladder cancer trial, demonstrating a significant reduction in disease progressi...
Feb 28, 2026